青岛大学学报（医学版）2025，Vol.61Issue(6)：891-895,5.DOI:10.11712/jms.2096-5532.2025.61.184
同步放化疗辅助贝伐单抗对复发性脑胶质瘤初步效果
Preliminary effect of concurrent chemoradiotherapy as an adjuvant therapy to bevacizumab in treatment of recurrent glioma
摘要
Abstract
Objective To investigate the preliminary effect of concurrent chemoradiotherapy as an adjuvant therapy to be-vacizumab in the treatment of recurrent glioma.Methods A total of 62 patients with recurrent glioma who were treated in Cangzhou Central Hospital from June 2019 to June 2022 were enrolled as subjects,and a retrospective analysis was performed for their clinical data.According to the treatment method,the patients were divided into control group and combination group,with 31 patients in each group.The patients in the control group received concurrent chemoradiotherapy with stereotactic radiotherapy and temozolomide chemotherapy,while those in the combination group received bevacizumab adjuvant therapy in addition to the regi-men of concurrent chemoradiotherapy in the control group.The two groups were compared in terms of short-term efficacy,progno-sis,toxic and side effects,and the change in immune function after treatment.Results Compared with the control group,the combination group had significantly higher objective response rate(64.5％us 38.7％,x2=4.133,P＜0.05)and disease control rate(93.6％vs 74.2％,x2=4.292,P＜0.05).Both groups had significant improvements in immune function parameters after treat-ment(t=8.914-19.231,all P＜0.05),and compared with the control group after treatment,the combination group had signifi-cantly higher levels of CD4+and CD4+/CD8+ratio and significantly greater changes in CD4+and CD4+/CD8+ratio,as well as a signifi-cantly lower level of CD8+and a significantly smaller change in CD8+(t=-14.353 to 21.831,all P＜0.05).There were no signifi-cant differences between the two groups in the incidence rates of toxic and side effects such as myelosuppression,hypertension,gastrointestinal reactions,fatigue,infections,and thrombocytopenia(all P＞0.05).Compared with the control group,the combi-nation group had significantly higher median progression-free survival,median overall survival,and 2-year survival rate(log-rank test,x2=4.509-7.646,all P＜0.05).The Cox proportional hazards regression model analysis showed that in the combination group,the hazard ratio(95％confidence interval)for progression-free survival and overall survival was 0.48(0.29-0.79)and 0.40(0.23-0.69),respectively,both of which were significantly lower than those in the control group(P＜0.001).Conclusion Con-current chemoradiotherapy as an adjuvant therapy to bevacizumab can significantly enhance the short-term treatment outcome of patients with recurrent glioma,and it can not only improve immune function,but also prolong survival time,with a favorable safe-ty profile.Therefore,it holds promise for clinical application.关键词
神经胶质瘤/复发/贝伐单抗/放射外科手术/放化疗,辅助/治疗结果/预后Key words
glioma/recurrence/bevacizumab/radiosurgery/chemoradiotherapy,adjuvant/treatment outcome/prognosis分类
医药卫生引用本文复制引用
刘永杰,梁赞,田丽丽..同步放化疗辅助贝伐单抗对复发性脑胶质瘤初步效果[J].青岛大学学报（医学版）,2025,61(6):891-895,5.基金项目
河北省医学科学研究课题计划项目(20241840) （20241840）
